Neurocrine Biosciences

Top biotech licensing deals of Q1 2023
Top biotech licensing deals of Q1 2023
BioSpace
biotech
licensing
Moderna Therapeutics
CytomX
Voyager Therapeutics
Neurocrine Biosciences
Kronos Bio
Genentech
Karuna Therapeutics
Goldfinch Bio
Flag link:
Neurocrine randomizes first patient in Phase II schizophrenia therapy trial
Neurocrine randomizes first patient in Phase II schizophrenia therapy trial
Clinical Trials Arena
Neurocrine Biosciences
clinical trials
NBI-1117568
schizophrenia
Flag link:
Sometimes, Clinical Trials Miss the Mark: Neurocrine, Akebia, Eliem and Athira
Sometimes, Clinical Trials Miss the Mark: Neurocrine, Akebia, Eliem and Athira
BioSpace
clinical trials
Neurocrine Biosciences
Akebia Therapeutics
Eliem Therapeutics
Athira Pharma
Flag link:
‘A negative trial, not a failed trial’: Neurocrine axes in-licensed tremor program on phase 2 data
‘A negative trial, not a failed trial’: Neurocrine axes in-licensed tremor program on phase 2 data
Fierce Biotech
Neurocrine Biosciences
NBI-827104
clinical trials
essential tremor
Flag link:
Why Neurocrine Biosciences Shares Fell Nearly 10% Today
Why Neurocrine Biosciences Shares Fell Nearly 10% Today
Motley Fool
Neurocrine Biosciences
earnings
Flag link:
Neurocrine raises a new monument to mental health in pandemic resilience campaign
Neurocrine raises a new monument to mental health in pandemic resilience campaign
Fierce Pharma
mental health
Neurocrine Biosciences
pandemic
Flag link:
Neurocrine launches Parkinson's therapy as COVID-19 related disruptions ease
Neurocrine launches Parkinson's therapy as COVID-19 related disruptions ease
Yahoo/Reuters
Neurocrine Biosciences
drug launches
Parkinson's Disease
pandemic
COVID-19
Ogentys
Flag link:
How Neurocrine Biosciences Crushed It in Q2
How Neurocrine Biosciences Crushed It in Q2
Motley Fool
Neurocrine Biosciences
earnings
Flag link:
Takeda Grants License To Neurocrine Biosciences For Seven Pipeline Programs
Takeda Grants License To Neurocrine Biosciences For Seven Pipeline Programs
NASDAQ
Takeda
Neurocrine Biosciences
psychiatry
schizophrenia
treatment-resistant depression
anhedonia
Flag link:
How Neurocrine Biosciences Crushed It in Q4
How Neurocrine Biosciences Crushed It in Q4
Motley Fool
Neurocrine Biosciences
earnings
Flag link:
Neurocrine signs $400M-plus deal with Idorsia for epilepsy drug
Neurocrine signs $400M-plus deal with Idorsia for epilepsy drug
Pharmaforum
Idorsia
Neurocrine Biosciences
epilepsy
pediatric epilepsy
ACT-709478
Flag link:
Why Earnings Season Could Be Great for Neurocrine Biosciences (NBIX)
Why Earnings Season Could Be Great for Neurocrine Biosciences (NBIX)
Yahoo/Zacks.com
Neurocrine Biosciences
earnings
Flag link:
Neurocrine Biosciences Posts Sizzling Sales Growth in Q2
Neurocrine Biosciences Posts Sizzling Sales Growth in Q2
Motley Fool
Neurocrine Biosciences
earnings
Flag link:
FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug
FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug
Yahoo/Zacks.com
Neurocrine Biosciences
FDA
Parkinson's Disease
opicapone
Flag link:
Neurocrine’s Opicapone Plus Levodopa Improves Parkinson’s Symptoms
Neurocrine’s Opicapone Plus Levodopa Improves Parkinson’s Symptoms
BioSpace
Neurocrine Biosciences
clinical trials
opicapone
Parkinson's Disease
Flag link:
2 Biotech Takeout Targets Perfect for Biogen
2 Biotech Takeout Targets Perfect for Biogen
Motley Fool
Biogen
M&A
SAGE Therapeutics
Neurocrine Biosciences
Flag link:
Neurocrine, Jnana team up to discover CNS drugs
Neurocrine, Jnana team up to discover CNS drugs
Fierce Biotech
Neurocrine Biosciences
Jnana Therapeutics
small molecule drugs
CNS
drug discovery
Flag link:
From near non-existence to major biotech star: Neurocrine's journey
From near non-existence to major biotech star: Neurocrine's journey
San Diego Tribune, CA
Neurocrine Biosciences
Flag link:
3 Biotech Stocks With Major Potential Catalysts in July
3 Biotech Stocks With Major Potential Catalysts in July
Yahoo/Motley Fool
Neurocrine Biosciences
AbbVie
Progenics
INSYS Therapeutics
Elagolix
endometriosis
Azedra
adrenal tumors
Syndros
Flag link:
3 Biotechs That Could Get Big Boosts in April
3 Biotechs That Could Get Big Boosts in April
Motley Fool
biotech
GW Pharma
Epidiolex
Incyte
olumiant
baricitinib
Neurocrine Biosciences
Elagolix
Flag link:

Pages